Section 301 is a powerful tool for addressing foreign policies that distort global markets and disadvantage American producers. When foreign governments explicitly pursue overproduction and then export the resulting surplus into the United States, the effect is to displace domestic output and deter new investment in American manufacturing.
Section 301 actions against a particular country or group of countries are more likely to merely shift international supply chains as opposed to growing domestic productive output.
For the first time, the new portal provides the American public with detailed access to reported foreign funding, including gifts and contracts from entities designated as “entities of concern” on nine federal government watchlists.
CPA urges the administration to move swiftly to deploy Section 232 investigations through the U.S. Department of Commerce as the most durable and effective tool available to restore American industrial capacity.
Today’s SCOTUS ruling should encourage the administration to refocus and expand its Section 232 efforts.
CPA strongly supports Senator Cassidy and Whitehouse’s Last Sale Valuation Act because it closes a long-standing loophole that has allowed multinational importers to artificially understate the value of goods entering the United States.
The Tax Foundation’s calculation simply assumes the approximate $132 billion in new 2025 tariff revenue is paid directly by households, dividing that figure across 134.8 million households to produce an average estimate of a $1,000 annual burden per household.
This Interim Agreement framework reflects a long overdue acknowledgment that essential medicine supply chains cannot be left to foreign dominance, particularly by India or an adversary like China.
As highlighted in the Oval Office at the White House this week, Clarios played a part in the launch of ‘Project Vault,’ a major initiative to strengthen U.S. critical minerals security and safeguard American battery supply chains from global disruptions.
CPA this week applauded the acquisition of Nivagen Pharmaceuticals by member company, PAI Pharma (PAI), of Greenville, SC and Sacramento, CA.
